重组人脑利钠肽联合美托洛尔治疗冠心病合并慢性心力衰竭患者的疗效  

Raoeutic effect of recombinant human brain natriuretic peptide combined with metoprolol on patients with coronary heart disease complicated with chronic heart failure

作　　者：李博[1] 张于[1] 吴曼[1] 张岚岚 谢飞 张媛媛 LI Bo;ZHANG Yu;WU Man;ZHANG Lanlan;XIE Fei;ZHANG Yuanyuan(Tangshan People's Hos pital,Tangshan 063000,China)

机构地区：[1]河北省唐山市人民医院,063000

出　　处：《中国煤炭工业医学杂志》2023年第4期390-394,共5页Chinese Journal of Coal Industry Medicine

基　　金：2022年度河北省医学科学研究课题计划(编号:20221824)。

摘　　要：目的探讨重组人脑利钠肽联合美托洛尔治疗冠心病合并慢性心力衰竭患者的疗效。方法选择2020年6月—2022年6月该院重症医学科诊治的97例冠心病合并慢性心力衰竭患者为研究对象,依据是否应用重组人脑利钠肽分为对照组49例和观察组48例。对照组给予常规治疗及美托洛尔治疗,观察组在对照组治疗基础上联合重组人脑利钠肽治疗;比较对照组和观察组治疗4周后二组患者治疗效果的差别;比较对照组和观察组治疗前和治疗2周后脑钠肽含量的变化及区别;比较对照组和观察组治疗前和治疗2周后每搏输出量(strokvolume,SV)、每分钟心输出量(cardiacoutput,CO)以及左室射血分数(leftventricular ejectionfraction,LVEF)的心功能指标的变化及差别;比较对照组和观察组治疗4周恶心、呕吐、低血压及头痛等治疗时出现的副反应。结果对照组和观察组治疗4周后观察组的总有效率高于对照组的总有效率,并且差异均具有统计学意义(P<0.05);观察组治疗2周后每搏输出量(SV)、每分钟心输出量(CO)以及左室射血分数(LVEF)的心功能指标明显高于对照组,差异有统计学意义(P<0.05);对照组和观察组治疗4周后观察组脑钠肽含量明显低于对照组,差异有统计学意义(P<0.05);二组患者治疗4周观察组出现恶心、呕吐、低血压及头痛等治疗时出现的副反应发生率低于对照组,差异有统计学意义(P<0.05)。结论重组人脑利钠肽联合美托洛尔治疗冠心病合并慢性心力衰竭患者能在一定程度上改善患者心功能,提高治疗效果,对于降低脑钠肽的水平也能起到一定作用,并能一定程度上降低治疗过程中副反应的发生。Objective To explore the efficacy analysis of the combined treatment of coronary heart disease in patients with recombinant human cerebral sodium peptide with Ametolor. Methods Ninety-seven patients with coronary heart disease and chronic heart failure diagnosed in the intensive care department of the hospital from June 2020 to June 2022 were selected as the study subjects, and divided into forty-nine cases in the control group and forty-eight cases in the observation group according to whether or not recombinant human brain natriuretic peptide was applied.The control group was given routine treatment and metoprolol treatment.The combined treatment group was treated with recombinant human brain natriuretic peptide on the basis of the control group.Compare the difference of treatment effect between the control group and the combined treatment group after four weeks of treatment;Compare the changes and differences of brain natriuretic peptide content between the control group and the combined treatment group before and after treatment for two weeks;The changes and differences of cardiac function indexes of Strok Volume(SV),Cardiac output(CO) and Left ventricular ejection fraction(LVEF) were compared between the control group and the combined treatment group before treatment and two weeks after treatment.The side effects of nausea, vomiting, hypotension and headache were compared between the control group and the combined treatment group after 4 weeks. Results After four weeks of treatment, the total effective rate of the combined treatment group was higher than that of the control group, and the difference was statistically significant(P<0.05);The cardiac function indexes of stroke volume(SV),cardiac output per minute(CO) and left ventricular ejection fraction(LVEF) in the combined treatment group were significantly higher than those in the control group after two weeks of treatment(P<0.05);After 4 weeks of treatment, brain natriuretic peptide content in the combined treatment group was significantly lower than tha

关 键 词：重组人脑利钠肽 美托洛尔 慢性心力衰竭 冠心病 

分 类 号：R54[医药卫生—心血管疾病]